Regeneron's Trading Volume Surges 40.54% to $546 Million Ranking 212th in Stock Market

On July 22, 2025, Regeneron's trading volume reached $546 million, marking a 40.54% increase from the previous day, ranking 212th in the day's stock market. Regeneron Pharmaceuticals (REGN) has risen for two consecutive days, with a total increase of 3.39% over the past two days.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Eylea (aflibercept) for the treatment of diabetic retinopathy. This approval is a significant milestone for Regeneron, as it expands the indications for Eylea, which is already approved for the treatment of wet age-related macular degeneration and macular edema following retinal vein occlusion.

In addition to the FDA approval, Regeneron has also reported positive results from its Phase 3 clinical trial for REGN4210, an investigational monoclonal antibody for the treatment of atopic dermatitis. The trial met its primary endpoint, demonstrating a statistically significant improvement in the Eczema Area and Severity Index (EASI) score compared to placebo. These results are expected to support the company's plans to submit a Biologics License Application (BLA) to the FDA in the near future.

Regeneron's pipeline continues to show promise, with several other investigational drugs in various stages of clinical development. The company's strong portfolio of approved and investigational drugs positions it well to continue driving growth and innovation in the biopharmaceutical industry.